Filing Details

Accession Number:
0001209191-21-043467
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-28 16:01:51
Reporting Period:
2021-06-24
Accepted Time:
2021-06-28 16:01:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1322505 Albireo Pharma Inc. ALBO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1741553 Jason Duncan C/O Albireo Pharma, Inc.
10 Post Office Square, Suite 1000
Boston MA 02109
Chief Legal Officer And Gc No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-24 9,137 $24.04 17,117 No 4 M Direct
Common Stock Acquisiton 2021-06-24 863 $24.67 17,980 No 4 M Direct
Common Stock Disposition 2021-06-24 10,000 $36.38 7,980 No 4 S Direct
Common Stock Acquisiton 2021-06-25 6,300 $24.67 14,280 No 4 M Direct
Common Stock Disposition 2021-06-25 6,300 $36.22 7,980 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-06-24 9,137 $0.00 9,137 $24.04
Common Stock Stock Option (right to buy) Disposition 2021-06-24 863 $0.00 863 $24.67
Common Stock Stock Option (right to buy) Disposition 2021-06-25 6,300 $0.00 6,300 $24.67
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,063 2029-01-21 No 4 M Direct
30,637 2030-01-20 No 4 M Direct
24,337 2030-01-20 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. Represents 292 shares of common stock and 7,688 restricted stock units. Includes 131 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2021.
  5. This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023.
  6. This option vested as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021.